Bringing the fundamentals into focus…
Back to AnaptysBio, Inc.
How AnaptysBio, Inc. stacks up
ANAB · against 1,336 other Healthcare companies
Valuation
83/ 100
Near the top of its peers.
Ranked #222 of 1,337 · scores higher than 83% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 80–89, including ANAB · Click a bar to see the companies
Why valuation scores 83?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- lower earnings for the price paid: weaker than 67% of peers. Earnings yield: 13.7% vs peer median 1.5%
- EBITDA yield is close to the peer norm. EBITDA yield: 4.3% vs peer median 4.0%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.3% vs peer median 0.0%
Metric by metric
Position: dot = ANAB, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ANAB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -2.0% | 1.5% | 33% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 4.3% | 4.2% | 50% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | 0.3% | -1.0% | 54% | 20% | |
| Book yieldHigher is better · 1,306 reported | 0.7% | 37.9% | 6% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ANAB| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 222 | 2.05T KRW (≈$1.5B) | 83 | 81 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score